보고서 요약(국문)

개요
전 세계 유행성 각결막염 시장은 2022년 XX억 달러에 달했으며, 2023년부터 2030년까지 연평균 XX%의 성장률로 2030년에는 XX백만 달러에 이를 것으로 예상됩니다.
유행성 각결막염(아데노바이러스성 각결막염)은 아데노바이러스에 의해 발생하는 전염성 안구 감염 질환입니다. 일반적으로 갑작스러운 통증과 충혈, 눈물 분비를 동반한 결막염으로 나타납니다.
가장 흔한 원인균은 8형과 37형 아데노바이러스입니다. 오염된 안과 검사 도구 및 치료, 감염된 눈과의 접촉, 염소 소독이 제대로 되지 않은 수영장, 기타 오염된 물건을 통해 전파될 수 있습니다. 최대 절반의 환자에서 각막 흉터가 발생하며, 일부 환자에서는 시력 저하가 장기간 지속될 수 있습니다.

시장 동향
바이러스성 결막염의 증가하는 부담
바이러스성 결막염의 증가하는 부담은 시장 성장의 중요한 동인으로 작용합니다. 유행성 각결막염(EKC)은 각막 염증을 유발하는 전염성이 매우 높은 바이러스성 결막염의 한 형태입니다.
결막염은 가장 흔한 눈 충혈 원인 중 하나이며 모든 연령대와 사회경제적 계층의 환자에게 영향을 미칩니다. 바이러스성 결막염은 감염성 결막염의 대부분을 차지하며, 최대 75%에 달합니다.
또한, 바이러스성 결막염 사례의 약 90%는 아데노바이러스에 의해 발생합니다. HAdV 3, 4, 7형에 의한 인두결막열(PCF)을 앓는 소아는 급성 여포성 결막염 외에도 발열, 인두염, 귓바퀴 주위 림프절 비대를 경험합니다.

또한, 미국 국립보건원(NIH) 보고서에 따르면 감염성 결막염 사례의 6%에서 60%가 유행성 각결막염(EKC)에 의해 발생합니다. 안과 응급실을 방문한 환자의 8%가 EKC를 앓고 있는 것으로 나타났습니다. 따라서 EKC는 가장 흔한 바이러스성 안질환이며, 질병으로 인해 사람들이 일을 할 수 없게 되어 상당한 경제적 손실을 초래합니다.
더불어, 유행성 각결막염에 대한 인식 증가와 치료제 임상 시험 증가와 같은 주요 성장 동력이 향후 시장 성장을 견인할 것으로 예상됩니다.
치료제 관련 부작용
덱사메타손 점안액과 같은 치료제는 알레르기 및 특정 질환으로 인한 눈의 염증을 치료하는 데 사용됩니다. 이 약물은 시야 흐림, 눈 충혈, 눈의 박동성 통증, 눈 가려움증과 같은 부작용을 유발할 수 있습니다. 따라서 이러한 요인들이 시장 성장을 저해할 것으로 예상됩니다.

시장 세분화 분석
전 세계 유행성 각결막염 시장은 치료제, 투여 경로, 유통 채널 및 지역별로 세분화됩니다.
치료제는 시장 점유율의 약 42.5%를 차지했습니다.
유행성 각결막염(EKC)은 아데노바이러스 그룹에 의해 발생하는 바이러스성 결막염입니다. 유행성 각결막염은 전염성이 매우 높으며 유행성으로 발생하는 경향이 있습니다. 치료제는 예측 기간 동안 가장 큰 시장 점유율을 차지할 것으로 예상됩니다.
치료는 주로 증상 완화(냉찜질 및 인공눈물)에 중점을 둡니다. 일부 환자에게는 항바이러스제(시도포비르)와 사이클로스포린 점안액이 시도되었습니다. 심한 경우에는 국소 코르티코스테로이드가 처방되기도 하는데, 염증 증상 완화에는 도움이 되지만 회복 시간을 크게 단축시키지는 못합니다.
시도포비르는 바이러스 복제 주기를 단축시켜 예방 조치로 유용하다는 것이 입증되었습니다. 유행성 각결막염의 치료 및 예방에 가장 효과적인 국소 항바이러스제 중 하나는 시도포비르일 수 있습니다.
지역 분석
북미는 전 세계 유행성 각결막염 시장에서 상당한 점유율을 차지할 것으로 예상됩니다.
전 세계 유행성 각결막염 시장은 북미, 유럽, 아시아 태평양, 남미, 중동 및 아프리카로 구분됩니다.
북미는 유행성 각결막염의 유병률 증가 및 의료비 지출 증가와 같은 요인으로 인해 상당한 시장 점유율을 유지해 왔으며, 이러한 추세는 예측 기간 동안 지속될 것으로 예상됩니다.
예를 들어, 급성 결막염 환자 10만 명당 바이러스성 결막염 발생률은 약 8만 명입니다. 아데노바이러스로 인한 바이러스성 결막염 발생률은 바이러스성 결막염 환자 10만 명당 약 6만 5천 명에서 9만 명 사이입니다.

COVID-19 영향 분석
COVID-19 팬데믹은 전 세계 유행성 각결막염 치료 시장에 상당한 영향을 미쳤습니다. 2020년 초 팬데믹 발생으로 인해 광범위한 봉쇄와 제한 조치가 시행되었고, 이는 전 세계적으로 정기적인 진단, 치료, 신약 출시 및 상담에 영향을 미쳤습니다.
팬데믹 발생으로 인해 많은 제약 회사 및 의료기기 제조업체는 인력 부족에 직면했고, 봉쇄 조치로 인해 직원들이 업무 현장으로 이동할 수 없었습니다. 따라서 이러한 요인들로 인해 유행성 각결막염 치료 시장은 예측 기간 동안 중간 정도의 영향을 받을 것으로 예상됩니다.

시장 세분화
의약품별
• 덱사메타손
• 플루오로메톨론
• 안과용 프레드니솔론
• 리멕솔론 1%
• 시도포비르
• 포비돈 요오드 2%
투여 경로별
• 국소
• 경구
유통 채널별
• 병원 약국
• 소매 약국
• 온라인 약국
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 스페인
o 이탈리아
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
• 중동 및 아프리카
경쟁 환경
시장의 주요 글로벌 업체로는 Sandoz Group AG, Xenon Pharmaceuticals Inc, Bausch + Lomb Corp, Rayner Group, AdvaCare Pharma, Eyeris Vision Care 등이 있습니다. 주요 기업으로는 Pvt. Ltd., AbbVie Inc., Alcon AG, Viatris Inc., Aspen Pharmacare Holdings Limited 등이 있습니다.

주요 동향
• 2023년 7월, Harrow는 Santen의 브랜드 안과용 의약품 포트폴리오를 인수했습니다. 여기에는 FLAREX, NATACYN, TOBRADEX ST, VERKAZIA, ZERVIATE의 미국 및 캐나다 판매권과 비처방 브랜드인 FRESHKOTE 및 Cationorm PLUS가 포함됩니다.
보고서 구매 이유

• 의약품, 투여 경로, 유통 채널 및 지역별 전 세계 유행성 각결막염 시장 세분화를 시각화하고 주요 상업 자산 및 기업을 파악하기 위함입니다.

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 발굴하기 위함입니다.

• 모든 세그먼트를 포함한 유행성 각결막염 시장 수준의 다양한 데이터가 담긴 Excel 데이터 시트가 제공됩니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석이 담긴 PDF 보고서입니다.

• 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 자료를 엑셀 파일로 제공합니다.
글로벌 유행성 각결막염 치료 시장 보고서는 약 61개의 표, 63개의 그림, 그리고 185페이지 분량으로 구성됩니다.
2023년 주요 고객층
• 제조업체/구매자
• 산업 투자자/투자은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Epidemic Keratoconjunctivitis Market reached US$ XX billion in 2022 and is expected to reach US$ XX million by 2030 growing at a CAGR of XX% during the forecast period 2023-2030.
Epidemic keratoconjunctivitis also known as adenoviral keratoconjunctivitis is a contagious eye infection, a type of adenovirus disease caused by adenoviruses. It typically presents as conjunctivitis with a sudden onset of a painful red eye, and watery discharge.
The type 8 and 37 adenoviruses are the most prevalent cause. They can spread by contaminated eye inspection tools and eye treatments, contact with diseased eyes, poorly chlorinated swimming pools, and other contaminated things. Corneal scarring occurs in up to half of cases and the blurred vision can continue for a long time in some people.
Market Dynamics
The increasing burden of viral conjunctivitis
The increasing burden of viral conjunctivitis acts as a significant driver for market growth. Epidemic keratoconjunctivitis (EKC) is a highly contagious form of viral conjunctivitis that develops corneal inflammation.
Conjunctivitis is one of the most common causes of red-eye and affects patients of all ages and socioeconomic classes. Viral conjunctivitis is responsible for the majority of infectious conjunctivitis, accounting for up to 75% of cases.
Additionally, an estimated 90% of cases of viral conjunctivitis are brought on by adenoviruses. Children with pharyngoconjunctival fever (PCF) caused by HAdV types 3, 4, and 7 experience fever, pharyngitis, and periauricular lymphadenopathy in addition to acute follicular conjunctivitis.
Also, according to the National Institute of Health Reports, between 6% and 60% of instances of infectious conjunctivitis are caused by EKC. It was discovered that 8% of patients presenting to an eye clinic's emergency room had EKC. Hence, EKC is the most prevalent viral eye illness and results in significant financial losses since it prevents people from working.
Furthermore, significant growth drivers such as the growing awareness of epidemic keratoconjunctivitis, and increasing clinical trials for treatment drugs are expected to drive the market in the forecast period.
Side effects associated with treatment drugs
Treatment drugs such as dexamethasone eye drops are used to treat inflammation of the eyes caused by allergies and certain conditions. This particular drug can cause blurred vision, redness of the eyes, throbbing pain of the eye, and itching of the eyes. Hence, the above factors are expected to hamper the market growth.
Segment Analysis
The global epidemic keratoconjunctivitis market is segmented based on medication, route of administration, distribution channel and region.
Medication accounted for approximately 42.5% of the market share
Epidemic keratoconjunctivitis (EKC) is a viral conjunctivitis caused by a group of adenoviruses. Epidemic keratoconjunctivitis is highly contagious and has a tendency to occur in epidemics. Medications are expected to hold the largest market share over the period forecast.
Treatment is mostly symptomatic (cold compresses and artificial tears). Antiviral (cidofovir ) and cyclosporine eye drops were tried in some patients. Topical corticosteroids are often prescribed in severe cases and while they do assist in reducing inflammatory symptoms, they do not significantly reduce recovery time.
It has been demonstrated that cidofovir can shorten the viral replication cycle and is useful as a preventative measure. One of the most effective topical antiviral medications for treating and preventing epidemic keratoconjunctivitis may be cidofovir.
Geographical Analysis
North America is expected to hold a significant position in the global epidemic keratoconjunctivitis market share
The global epidemic keratoconjunctivitis market is segmented into North America, Europe, Asia Pacific, South America, Middle East, and Africa.
North America has maintained a significant market proportion due to factors such as the rising prevalence of epidemic keratoconjunctivitis, and increasing healthcare expenditure, this trend is anticipated to continue throughout the forecast period.
For instance, the incidence of viral conjunctivitis is approximately 80,000 per 100,000 cases with acute conjunctivitis. The incidence of viral conjunctivitis caused by adenoviruses approximately ranges from 65,000 to 90,000 cases per 100,000 cases with viral conjunctivitis.
COVID-19 Impact Analysis
The COVID-19 pandemic has had a significant impact on the global epidemic keratoconjunctivitis treatment market. The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting regular diagnoses, treatments, drug launches, and consultations worldwide.
With the outbreak of the pandemic, many pharmaceutical or medical device manufacturing units faced labor shortages and were unable to travel to work due to lockdown restrictions. Therefore, owing to the above factors, the epidemic keratoconjunctivitis treatment market is expected to be moderately affected over the forecast period.
Market Segmentation
By Medication
• Dexamethasone
• Fluorometholone
• Ophthalmic Prednisolone
• Rimexolone 1%
• Cidofovir
• 2% Povidone-iodine
By Route of Administration
• Topical
• Oral
By Distribution Channel
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the market include Sandoz Group AG, Xenon Pharmaceuticals Inc, Bausch + Lomb Corp, Rayner Group, AdvaCare Pharma, Eyeris Vision Care Pvt. Ltd., AbbVie Inc., Alcon AG, Viatris Inc., Aspen Pharmacare Holdings Limited among others.
Key Developments
• In July 2023, Harrow acquired Santen’s branded ophthalmic portfolio that includes U.S. and Canadian Commercial Rights to FLAREX, NATACYN, TOBRADEX ST, VERKAZIA, ZERVIATE, and Non-Prescription Brands FRESHKOTE and Cationorm PLUS.
Why Purchase the Report?
• To visualize the global epidemic keratoconjunctivitis market segmentation based on medication, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of epidemic keratoconjunctivitis market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global epidemic keratoconjunctivitis treatment market report would provide approximately 61 tables, 63 figures, and 185 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Medication
3.2. Snippet by Route of Administration
3.3. Snippet by Distribution Channel
3.4. Snippet by Region
4. Market Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. The increasing burden of epidemic keratoconjunctivitis
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. Side effects associated with treatment drugs
4.1.2.2. XX
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Medication
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
7.1.2. Market Attractiveness Index, By Medication
7.2. Dexamethasone*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.2.3. Fluorometholone
7.2.4. Ophthalmic Prednisolone
7.2.5. Rimexolone 1%
7.2.6. Cidofovir
7.2.7. 2% Povidone-iodine
8. By Route of Administration
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.1.2. Market Attractiveness Index, By Route of Administration
8.2. Topical*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Oral
9. By Distribution Channel
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Hospital Pharmacy *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Retail Pharmacy
9.4. Online Pharmacy
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medication
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Sandoz Group AG
12.1.1. Company Overview
12.1.2. Diagnostic technique Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Xenon Pharmaceuticals Inc
12.3. Bausch + Lomb Corp
12.4. Rayner Group
12.5. AdvaCare Pharma
12.6. Eyeris Vision Care Pvt. Ltd.
12.7. AbbVie Inc.
12.8. Alcon AG
12.9. Viatris Inc.
12.10. Aspen Pharmacare Holdings Limited
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

Sandoz Group AG, 4.	Key Developments, Xenon Pharmaceuticals Inc, Bausch + Lomb Corp, Rayner Group, AdvaCare Pharma, Eyeris Vision Care Pvt. Ltd., AbbVie Inc., Alcon AG, Viatris Inc., Aspen Pharmacare Holdings Limited

표 목록 (Tables)

List of Tables

Table 1 Global Epidemic Keratoconjunctivitis Market Value, By Medication, 2023, 2027 & 2031 (US$ Million)

Table 2 Global Epidemic Keratoconjunctivitis Market Value, By Route of Administration, 2023, 2027 & 2031 (US$ Million)

Table 3 Global Epidemic Keratoconjunctivitis Market Value, By Distribution Channel, 2023, 2027 & 2031 (US$ Million)

Table 4 Global Epidemic Keratoconjunctivitis Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 5 Global Epidemic Keratoconjunctivitis Market Value, By Medication, 2023, 2027 & 2031 (US$ Million)

Table 6 Global Epidemic Keratoconjunctivitis Market Value, By Medication, 2022-2031 (US$ Million)

Table 7 Global Epidemic Keratoconjunctivitis Market Value, By Route of Administration, 2023, 2027 & 2031 (US$ Million)

Table 8 Global Epidemic Keratoconjunctivitis Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 9 Global Epidemic Keratoconjunctivitis Market Value, By Distribution Channel, 2023, 2027 & 2031 (US$ Million)

Table 10 Global Epidemic Keratoconjunctivitis Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 11 Global Epidemic Keratoconjunctivitis Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 12 Global Epidemic Keratoconjunctivitis Market Value, By Region, 2022-2031 (US$ Million)

Table 13 North America Epidemic Keratoconjunctivitis Market Value, By Medication, 2022-2031 (US$ Million)

Table 14 North America Epidemic Keratoconjunctivitis Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 15 North America Epidemic Keratoconjunctivitis Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 16 North America Epidemic Keratoconjunctivitis Market Value, By Country, 2022-2031 (US$ Million)

Table 17 South America Epidemic Keratoconjunctivitis Market Value, By Medication, 2022-2031 (US$ Million)

Table 18 South America Epidemic Keratoconjunctivitis Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 19 South America Epidemic Keratoconjunctivitis Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 20 South America Epidemic Keratoconjunctivitis Market Value, By Country, 2022-2031 (US$ Million)

Table 21 Europe Epidemic Keratoconjunctivitis Market Value, By Medication, 2022-2031 (US$ Million)

Table 22 Europe Epidemic Keratoconjunctivitis Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 23 Europe Epidemic Keratoconjunctivitis Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 24 Europe Epidemic Keratoconjunctivitis Market Value, By Country, 2022-2031 (US$ Million)

Table 25 Asia-Pacific Epidemic Keratoconjunctivitis Market Value, By Medication, 2022-2031 (US$ Million)

Table 26 Asia-Pacific Epidemic Keratoconjunctivitis Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 27 Asia-Pacific Epidemic Keratoconjunctivitis Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 28 Asia-Pacific Epidemic Keratoconjunctivitis Market Value, By Country, 2022-2031 (US$ Million)

Table 29 Middle East & Africa Epidemic Keratoconjunctivitis Market Value, By Medication, 2022-2031 (US$ Million)

Table 30 Middle East & Africa Epidemic Keratoconjunctivitis Market Value, By Route of Administration, 2022-2031 (US$ Million)

Table 31 Middle East & Africa Epidemic Keratoconjunctivitis Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 32 Sandoz Group AG: Overview

Table 33 Sandoz Group AG: Product Portfolio

Table 34 Sandoz Group AG: Key Developments

Table 35 Xenon Pharmaceuticals Inc: Overview

Table 36 Xenon Pharmaceuticals Inc: Product Portfolio

Table 37 Xenon Pharmaceuticals Inc: Key Developments

Table 38 Bausch + Lomb Corp: Overview

Table 39 Bausch + Lomb Corp: Product Portfolio

Table 40 Bausch + Lomb Corp: Key Developments

Table 41 Rayner Group: Overview

Table 42 Rayner Group: Product Portfolio

Table 43 Rayner Group: Key Developments

Table 44 AdvaCare Pharma: Overview

Table 45 AdvaCare Pharma: Product Portfolio

Table 46 AdvaCare Pharma: Key Developments

Table 47 Eyeris Vision Care Pvt. Ltd.: Overview

Table 48 Eyeris Vision Care Pvt. Ltd.: Product Portfolio

Table 49 Eyeris Vision Care Pvt. Ltd.: Key Developments

Table 50 AbbVie Inc.: Overview

Table 51 AbbVie Inc.: Product Portfolio

Table 52 AbbVie Inc.: Key Developments

Table 53 Alcon AG: Overview

Table 54 Alcon AG: Product Portfolio

Table 55 Alcon AG: Key Developments

Table 56 Viatris Inc.: Overview

Table 57 Viatris Inc.: Product Portfolio

Table 58 Viatris Inc.: Key Developments

Table 59 Aspen Pharmacare Holdings Limited: Overview

Table 60 Aspen Pharmacare Holdings Limited: Product Portfolio

Table 61 Aspen Pharmacare Holdings Limited: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Epidemic Keratoconjunctivitis Market Value, 2022-2031 (US$ Million)

Figure 2 Global Epidemic Keratoconjunctivitis Market Share, By Medication, 2022 & 2031 (%)

Figure 3 Global Epidemic Keratoconjunctivitis Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 4 Global Epidemic Keratoconjunctivitis Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 5 Global Epidemic Keratoconjunctivitis Market Share, By Region, 2022 & 2031 (%)

Figure 6 Global Epidemic Keratoconjunctivitis Market Y-o-Y Growth, By Medication, 2022-2031 (%)

Figure 7 Dexamethasone Epidemic Keratoconjunctivitis Market Value, 2022-2031 (US$ Million)

Figure 8 Fluorometholone Epidemic Keratoconjunctivitis Market Value, 2022-2031 (US$ Million)

Figure 9 Ophthalmic Prednisolone Epidemic Keratoconjunctivitis Market Value, 2022-2031 (US$ Million)

Figure 10 Rimexolone 1% Epidemic Keratoconjunctivitis Market Value, 2022-2031 (US$ Million)

Figure 11 Cidofovir Epidemic Keratoconjunctivitis Market Value, 2022-2031 (US$ Million)

Figure 12 2% Povidone-iodine Epidemic Keratoconjunctivitis Market Value, 2022-2031 (US$ Million)

Figure 13 Others Epidemic Keratoconjunctivitis Market Value, 2022-2031 (US$ Million)

Figure 14 Global Epidemic Keratoconjunctivitis Market Y-o-Y Growth, By Route of Administration, 2022-2031 (%)

Figure 15 Oral Route of Administration in Global Epidemic Keratoconjunctivitis Market Value, 2022-2031 (US$ Million)

Figure 16 Topical Route of Administration in Global Epidemic Keratoconjunctivitis Market Value, 2022-2031 (US$ Million)

Figure 17 Global Epidemic Keratoconjunctivitis Market Y-o-Y Growth, By Distribution Channel, 2022-2031 (%)

Figure 18 Hospital Pharmacy Distribution Channel in Global Epidemic Keratoconjunctivitis Market Value, 2022-2031 (US$ Million)

Figure 19 Retail Pharmacy Distribution Channel in Global Epidemic Keratoconjunctivitis Market Value, 2022-2031 (US$ Million)

Figure 20 Online Pharmacy Distribution Channel in Global Epidemic Keratoconjunctivitis Market Value, 2022-2031 (US$ Million)

Figure 21 Distribution Channel in Global Epidemic Keratoconjunctivitis Market Value, 2022-2031 (US$ Million)

Figure 22 Global Epidemic Keratoconjunctivitis Market Y-o-Y Growth, By Region, 2022-2031 (%)

Figure 23 North America Epidemic Keratoconjunctivitis Market Value, 2022-2031 (US$ Million)

Figure 24 Asia-Pacific Epidemic Keratoconjunctivitis Market Value, 2022-2031 (US$ Million)

Figure 25 Europe Epidemic Keratoconjunctivitis Market Value, 2022-2031 (US$ Million)

Figure 26 South America Epidemic Keratoconjunctivitis Market Value, 2022-2031 (US$ Million)

Figure 27 Middle East and Africa Epidemic Keratoconjunctivitis Market Value, 2022-2031 (US$ Million)

Figure 28 North America Epidemic Keratoconjunctivitis Market Value, 2022-2031 (US$ Million)

Figure 29 North America Epidemic Keratoconjunctivitis Market Share, By Medication, 2022 & 2031 (%)

Figure 30 North America Epidemic Keratoconjunctivitis Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 31 North America Epidemic Keratoconjunctivitis Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 32 North America Epidemic Keratoconjunctivitis Market Share, By Country, 2022 & 2031 (%)

Figure 33 South America Epidemic Keratoconjunctivitis Market Value, 2022-2031 (US$ Million)

Figure 34 South America Epidemic Keratoconjunctivitis Market Share, By Medication, 2022 & 2031 (%)

Figure 35 South America Epidemic Keratoconjunctivitis Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 36 South America Epidemic Keratoconjunctivitis Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 37 South America Epidemic Keratoconjunctivitis Market Share, By Country, 2022 & 2031 (%)

Figure 38 Europe Epidemic Keratoconjunctivitis Market Value, 2022-2031 (US$ Million)

Figure 39 Europe Epidemic Keratoconjunctivitis Market Share, By Medication, 2022 & 2031 (%)

Figure 40 Europe Epidemic Keratoconjunctivitis Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 41 Europe Epidemic Keratoconjunctivitis Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 42 Europe Epidemic Keratoconjunctivitis Market Share, By Country, 2022 & 2031 (%)

Figure 43 Asia-Pacific Epidemic Keratoconjunctivitis Market Value, 2022-2031 (US$ Million)

Figure 44 Asia-Pacific Epidemic Keratoconjunctivitis Market Share, By Medication, 2022 & 2031 (%)

Figure 45 Asia-Pacific Epidemic Keratoconjunctivitis Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 46 Asia-Pacific Epidemic Keratoconjunctivitis Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 47 Asia-Pacific Epidemic Keratoconjunctivitis Market Share, By Country, 2022 & 2031 (%)

Figure 48 Middle East & Africa Epidemic Keratoconjunctivitis Market Value, 2022-2031 (US$ Million)

Figure 49 Middle East & Africa Epidemic Keratoconjunctivitis Market Share, By Medication, 2022 & 2031 (%)

Figure 50 Middle East & Africa Epidemic Keratoconjunctivitis Market Share, By Route of Administration, 2022 & 2031 (%)

Figure 51 Middle East & Africa Epidemic Keratoconjunctivitis Market Share, By Distribution Channel, 2022 & 2031 (%)

Figure 52 Sandoz Group AG: Financials

Figure 53 Xenon Pharmaceuticals Inc: Financials

Figure 54 Bausch + Lomb Corp: Financials

Figure 55 Rayner Group: Financials

Figure 56 AdvaCare Pharma: Financials

Figure 57 Eyeris Vision Care Pvt. Ltd.: Financials

Figure 58 AbbVie Inc.: Financials

Figure 59 Alcon AG: Financials

Figure 60 Viatris Inc.: Financials

Figure 61 Aspen Pharmacare Holdings Limited: Financials

세계 유행성 각결막염 시장 – 2023-2030

Global Epidemic Keratoconjunctivitis Market - 2023-2030